Skip to main content
. 2023 Oct 22;10(33):2302498. doi: 10.1002/advs.202302498

Figure 5.

Figure 5

AB680 enhances the sensitivity to PD‐1 blockade for the treatment of orthotopic KPC allografts. A) Schematic representation of the therapy schedule for AB680 and anti‐PD‐1 in the KPC orthotopic model. B,C) Image (B) and tumor weight (C) of KPC orthotopic allografts from the Control, Anti‐PD‐1, and AB680+Anti‐PD‐1 groups (n = 6 samples per group). Data are presented as mean ± SD, with * p < 0.05 and ** p < 0.01 in Student's t‐test. D) Representative images of immunohistochemistry staining of CD8, Ki‐67, and Cleaved caspase‐3, and immunofluorescence staining of Granzyme B+CD8 T cells in the KPC allografts from the indicated treatment groups (n = 6 samples per group). Scale bar: 200 µm. E) Quantification of CD8, Ki‐67, and Cleaved caspase‐3% positive area, and Granzyme B+CD8+ cell number in the tumors of each group at the endpoint. n = 6 samples per group. Data are presented as mean ± SD, with * p < 0.05, ** p < 0.01, and *** p < 0.001 in Student's t‐test.